Moderna, Inc., a biotechnology business that develops messenger RNA (mRNA) treatments and vaccines, said today that Jorge Gomez will join the company as Chief Financial Officer, beginning May 9, 2022.
He will be a member of Moderna’s Executive Committee and will report to Stéphane Bancel, the company’s Chief Executive Officer. Since August 2019, Mr. Gomez has served as Executive Vice President and Chief Financial Officer of Dentsply Sirona, Inc. (Nasdaq: XRAY). He was in charge of the global finance organisation of Dentsply Sirona, which included strategic finance, FP&A, Accounting, Treasury, Tax, Corporate Audit and Investor Relations, as well as the Information Technology department.
Mr. Gomez was also in charge of the sustainability and ESG programme at Dentsply Sirona.
Prior to joining Dentsply Sirona, Mr. Gomez worked at Cardinal Health (NYSE: CAH), a Fortune 14 business, for 13 years, most recently as CFO and previously as Medical Segment CFO, Pharmaceutical Segment CFO, Corporate Treasurer, and Corporate Controller.
Prior to joining Cardinal Health, Mr. Gomez worked for General Motors in New York City, Singapore, Belgium, and Brazil, where he held progressive financial and business leadership roles.
Mr. Gomez holds a master’s degree in business administration from the University of Hartford and a bachelor’s degree in electrical engineering from Colombia’s National University.
Mr. Gomez is a member of the Xylem, Inc. (NYSE: XYL) and Pear Therapeutics Boards of Directors (Nasdaq: PEAR). Moderna’s current CFO, David Meline, has opted to retire and will continue to work as a consultant for the company to guarantee a smooth transition of the CFO post to Mr. Gomez.
Moderna has grown from a research-stage company advancing programmes in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas such as mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale in the ten years since its inception.
